Best of the Blog: IN VIVO, August 2008
Executive Summary
A better way to do risk-benefit: FDA is seeking a 'more formalized and comprehensive approach to the benefit/risk assessment.' Though there is obvious appeal for such a tool, but here's why it isn't going to workout as planned.